DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Legal & General Group Plc

Legal & General Group Plc trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 14.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,565,151 shares of the medical device company’s stock after selling 446,202 shares during the period. Legal & General Group Plc’s holdings in DexCom were worth $199,492,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Brophy Wealth Management LLC bought a new stake in shares of DexCom during the 3rd quarter worth about $337,000. Geode Capital Management LLC raised its holdings in shares of DexCom by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after purchasing an additional 214,136 shares in the last quarter. Coldstream Capital Management Inc. raised its holdings in shares of DexCom by 45.3% in the 3rd quarter. Coldstream Capital Management Inc. now owns 11,253 shares of the medical device company’s stock worth $781,000 after purchasing an additional 3,508 shares in the last quarter. Toronto Dominion Bank raised its holdings in shares of DexCom by 3.1% in the 3rd quarter. Toronto Dominion Bank now owns 204,522 shares of the medical device company’s stock worth $13,711,000 after purchasing an additional 6,227 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of DexCom in the 3rd quarter worth approximately $1,020,000. 97.75% of the stock is currently owned by institutional investors.

Insider Transactions at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares in the company, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is owned by insiders.

DexCom Trading Up 10.1 %

Shares of DXCM stock opened at $66.84 on Thursday. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $141.25. The stock has a market cap of $26.21 billion, a price-to-earnings ratio of 46.74, a P/E/G ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a fifty day moving average of $77.74 and a 200-day moving average of $76.63.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on DXCM shares. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Citigroup lifted their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Morgan Stanley lifted their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Cfra Research raised shares of DexCom to a “hold” rating in a research report on Friday, March 21st. Finally, Canaccord Genuity Group lifted their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.